Numerous systemic therapies are available for patients with metastatic ccRCC and include vascular endothelial growth factor (VEGF)‐targeted therapy and immune checkpoint inhibitors. The gene discussed is VEGFA; the disease is nonpapillary renal cell carcinoma.